首页> 外文期刊>Head and neck: Journal for the sciences and specialities of the head and neck >Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.
【24h】

Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.

机译:顺铂和5-氟尿嘧啶诱导化疗,然后放化疗或放疗单独治疗局部晚期可切除的喉和下咽癌:45名患者的单中心研究结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Induction chemotherapy with cisplatin and fluorouracil and radiotherapy is an effective alternative to surgery in patients with carcinoma of the larynx and hypopharynx who are treated for organ preservation. METHODS: We designed a protocol to evaluate the possibility of organ preservation in patients with advanced, resectable carcinoma of the larynx and hypopharynx. Forty-five eligible patients who were followed up between April 1999 and May 2001 were enrolled. Initially, these patients were treated with two cycles of induction chemotherapy consisting of cisplatin, 20 mg/m2/day on days 1 to 5, and 5-fluorouracil, 600 mg/m2/day by continuous infusion on days 1 to 5. Patients who had a complete response to chemotherapy were treated with definitive radiotherapy; patients who had a partial response to chemotherapy were treated with chemoradiotherapy. Cisplatin, 35 mg/m2/week, was introduced throughout the duration of radiotherapy. Patients who had no response or progressive disease underwent surgery with postoperative radiotherapy. Patients with N2 or N3 positive lymph nodes underwent neck dissection after the treatment. RESULTS: The mean age was 56.6 years (range, 34-75 years). The overall response rate to induction chemotherapy was 71.1%, with a 17.8% complete response rate and 53.3% partial response rate. With a median follow-up of 13.7 months, 23 (51.1%) of all patients and 63.3% of surviving patients have had a preservation of the larynx or hypopharynx and remain disease free. The most common toxicities were nausea and vomiting and mucositis. CONCLUSION: Organ preservation, with multimodality treatment, may be achievable in some of the patients with resectable, advanced larynx or hypopharynx cancers without apparent compromise of survival.
机译:背景:顺铂和氟尿嘧啶的诱导化学疗法以及放疗是治疗器官保存的喉癌和下咽癌的有效替代手术方法。方法:我们设计了一个协议,以评估晚期,可切除的喉和下咽癌患者器官保存的可能性。纳入了1999年4月至2001年5月间接受随访的45例合格患者。最初,这些患者接受了两次诱导化疗,包括在第1至5天每天20 mg / m2 /天和在1至5天连续输注5-氟尿嘧啶600 mg / m2 /天的两个诱导化疗周期。对化学疗法有完全反应的患者,应进行明确的放疗;对化疗有部分反应的患者接受放化疗治疗。在放疗过程中,每周使用35毫克/平方米/周的顺铂。无反应或进行性疾病的患者接受术后放射治疗。 N2或N3阳性淋巴结的患者在治疗后进行了颈部解剖。结果:平均年龄为56.6岁(范围34-75岁)。诱导化疗的总缓解率为71.1%,完全缓解率为17.8%,部分缓解率为53.3%。中位随访时间为13.7个月,所有患者中有23名(51.1%)和存活的患者中有63.3%保留了喉或下咽,并且没有疾病。最常见的毒性是恶心,呕吐和粘膜炎。结论:在某些可切除,晚期喉癌或下咽癌的患者中,采用多模式治疗可以实现器官保存而不会明显影响生存。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号